HC Wainwright Cuts Earnings Estimates for Compass Pathways

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Equities research analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for Compass Pathways in a research note issued to investors on Friday, August 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.43) per share for the quarter, down from their previous forecast of ($0.40). HC Wainwright currently has a “Buy” rating and a $65.00 price target on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.58) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.36) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($0.23) EPS, FY2029 earnings at $1.66 EPS and FY2030 earnings at $4.06 EPS.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49).

A number of other research analysts have also weighed in on the stock. Oppenheimer reissued an “outperform” rating on shares of Compass Pathways in a research report on Wednesday, August 5th. Morgan Stanley increased their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen cut shares of Compass Pathways from a “hold” rating to a “strong sell” rating in a research report on Saturday. Wells Fargo & Company began coverage on Compass Pathways in a research note on Monday, July 27th. They issued an “equal weight” rating and a $13.00 target price on the stock. Finally, TD Cowen reaffirmed a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Price Performance

CMPS opened at $13.18 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2.85 and a beta of 2.50. The firm’s fifty day moving average price is $12.57 and its two-hundred day moving average price is $9.39. Compass Pathways has a 1 year low of $3.97 and a 1 year high of $15.40.

Institutional Investors Weigh In On Compass Pathways

Several large investors have recently modified their holdings of CMPS. EverSource Wealth Advisors LLC lifted its stake in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in Compass Pathways during the fourth quarter valued at $38,000. Parallel Advisors LLC increased its position in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after buying an additional 7,183 shares during the last quarter. Advisory Services Network LLC purchased a new stake in Compass Pathways in the third quarter worth $41,000. Finally, North Star Investment Management Corp. raised its stake in shares of Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Key Headlines Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, substantially above the stock’s recent trading level. The firm still projects a potential transition to profitability, including estimated earnings of $1.66 per share in 2029 and $4.06 in 2030.
• Neutral Sentiment: The analyst now forecasts losses of $0.43 per share in the third quarter of 2026, $0.48 in the fourth quarter, and $1.58 for full-year 2026. Estimates remain negative through 2028, suggesting Compass Pathways is still dependent on successful clinical development and eventual commercialization of its pipeline.
• Negative Sentiment: HC Wainwright cut its 2027 EPS forecast to a $1.56 loss from an $0.85 loss, and reduced its 2028 forecast to a $0.23 loss from previously estimated earnings of $1.64 per share. The firm also lowered 2029 EPS to $1.66 from $3.78 and 2030 EPS to $4.06 from $6.59. Near-term quarterly estimates were also reduced, including Q2 2027 to a $0.41 loss, Q3 2027 to a $0.39 loss, and Q4 2027 to a $0.36 loss. These sharp cuts point to higher projected expenses, delayed revenue generation, or a slower-than-expected commercial ramp.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.